Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 25, 2015

View Archived Issues

has-miR-31 shows promise as a noninvasive biomarker for pharmaco-resistant epilepsy

Innovate UK gives grant to fund Mission Therapeutics' discovery of DUB inhibitors

Microvolume RTH-258 injection effective in treating neovascular age-related macular degeneration

FDA awards grants to boost product development for rare diseases

Q BioMed to acquire Mannin Research assets, including glaucoma candidate

Concert Pharmaceuticals reports phase I results for deuterated ivacaftor CTP-656

Eisai discovers inhibitor of interaction between TRAF6 and TNF superfamily receptors

Zai Lab enters collaboration and license agreement with UCB

Nanoglobular antimicrobial shows in vivo activity against B. cepacea

Purdue Pharma and AnaBios to form joint venture in chronic pain

Fexeric approved in Europe for hyperphosphatemia in patients with chronic kidney disease

Merck & Co. unveils HIV protease inhibitors

Bayer reports new CDK inhibitors

Genentech and Constellation Pharmaceuticals introduce demethylase inhibitors

Sichuan Haisco patents Wnt signaling inhibitors

University of California and McGill University present Mcl-1 inhibitors

Helsinn Healthcare divulges ghrelin receptor antagonists

Glucose-dependent peptide shows promise for diabetes

Esteve strengthens presence in ophthalmology through deal with VSY Biotechnology

CTI BioPharma plans 2015 NDA submission for pacritinib in the treatment of myelofibrosis

VivaGel BV approved in E.U. for bacterial vaginosis

EMA committee recommends European approval of Entresto

Oral treatment for wet AMD shows potential in phase I study, moves to phase II

EMA recommends approval of mepolizumab for severe refractory eosinophilic asthma

MetaStat's MenaCalc assay predicts overall survival in axillary node-negative breast cancer

GSK and Theravance plan Japanese filing for Relvar Ellipta for COPD

EMA CHMP grants accelerated assessment of Janssen's daratumumab for MM

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 15, 2026.
Ethyreal launches to treat the underlying cause of Graves’, TED
BioWorld
Ethyreal Bio Inc. has come out of stealth mode in order to disclose preclinical data for ETHY-001, its monoclonal antibody targeting thyroid stimulating hormone...
Microbiota modulates the antidepressant effects of GLP-1 analogues
BioWorld Science
Liraglutide, a glucagon-like peptide 1 (GLP-1) receptor agonist used in diabetes and obesity, could alleviate depression through a pathway that does not depend on...
Enliven’s phase I CML data Enable phase III with BCR/ABL1 bid
BioWorld
Tolerability is a key factor in the appeal of Enliven Therapeutics Inc.’s ELVN-001 for previously treated chronic myeloid leukemia (CML), which yielded positive...
EHA 2026: With new lenses, a changing view on pediatric cancers
BioWorld
In the most simplistic view, adult cancers occur because “immature cells are exposed to mutagens, accumulate mutations, and across life ultimately transform into...